| Literature DB >> 36045722 |
Yan Feng1, Zhijun Li2, Changhao Xie2, Fanglin Lu1.
Abstract
This study explored the correlation between peripheral blood CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+, CD3-/CD16+ CD56+, and CD3-CD19+ and disease activity of different subtypes of systemic lupus erythematosus (SLE). The percentages of CD3+, CD3+/CD4+, CD3+/CD8+, CD4+/CD8+, CD3-/CD16+ CD56+, and CD3-CD19+ in the peripheral blood of patients (n = 80) classified into lupus nephritis, blood involvement, and joint involvement and SLE in different active stages were detected by flow cytometry. Their correlations with baseline clinical experimental indicators of SLE patients' SLE disease activity index score (SLEDAI) and complement C3 were analyzed. The results showed that CD3+, CD3+/CD4+, and CD3+/CD8+ at baseline level were negatively correlated with SLEDAI scores. These were positively correlated with C3. In conclusion, T-lymphocyte subpopulations are closely related to SLE activity and can be used as reference indicators to evaluate the SLE activity.Entities:
Keywords: complement C3; disease activity; flow cytometry; lymphocyte; systemic lupus erythematosus
Year: 2022 PMID: 36045722 PMCID: PMC9372708 DOI: 10.1515/biol-2022-0093
Source DB: PubMed Journal: Open Life Sci ISSN: 2391-5412 Impact factor: 1.311
Results of peripheral blood lymphocyte subpopulation testing in the LN and non-LN Groups of SLE (mean ± standard deviation)
| Group |
| CD3+ (%) | CD3+/CD4+ (%) | CD3+/CD8+ (%) | CD4+/CD8+ | CD3−/CD16+CD56+ (%) | CD3−/CD19+ (%) |
|---|---|---|---|---|---|---|---|
| LN | 30 | 72.17 ± 7.13 | 25.27 ± 3.99 | 46.57 ± 6.3 | 0.55 ± 0.11 | 6.13 ± 2.05 | 6.17 ± 2.07 |
| Non-LN | 50 | 69.56 ± 6.36 | 28.64 ± 5.11 | 40.52 ± 3.97 | 0.71 ± 0.17 | 9.08 ± 1.96 | 6.4 ± 1.87 |
|
| 1.646 | −3.286 | 4.727 | −4.917 | −6.337 | −0.506 | |
|
| 0.105 | 0.002 | 0.001 | 0.001 | 0.001 | 0.615 |
Results of peripheral blood lymphocyte subpopulations in the blood and non-blood groups of SLE (mean ± standard deviation)
| Group |
| CD3+ (%) | CD3+/CD4+ (%) | CD3+/CD8+ (%) | CD4+/CD8+ | CD3−/CD16+CD56+ (%) | CD3−/CD19+ (%) |
|---|---|---|---|---|---|---|---|
| Blood | 55 | 70.93 ± 5.73 | 26.42 ± 4.43 | 44.51 ± 4.98 | 0.60 ± 0.16 | 7.95 ± 2.63 | 6.35 ± 1.83 |
| Non-blood | 25 | 69.88 ± 8.23 | 29.40 ± 5.68 | 39.36 ± 5.28 | 0.75 ± 0.12 | 8.00 ± 2.04 | 6.36 ± 2.06 |
|
| 0.576 | −2.32 | 4.11 | −4.693 | −0.1 | −0.03 | |
|
| 0.568 | 0.026 | 0.001 | 0.001 | 0.92 | 0.976 |
Results of peripheral blood lymphocyte subpopulations in the joint and non-joint groups of SLE (mean ± standard deviation)
| Group |
| CD3+ (%) | CD3+/CD4+ (%) | CD3+/CD8+ (%) | CD4+/CD8+ | CD3−/CD16+CD56+ (%) | CD3−/CD19+ (%) |
|---|---|---|---|---|---|---|---|
| Joint | 36 | 68.64 ± 5.27 | 26.69 ± 3.30 | 42.47 ± 5.90 | 0.64 ± 0.14 | 8.19 ± 1.86 | 6.17 |
| Non-joint | 44 | 71.5 ± 6.52 | 28.34 ± 5.13 | 42.75 ± 4.62 | 0.68 ± 0.17 | 7.91 ± 2.02 | 6.43 |
|
| −2.17 | −1.73 | −0.23 | −0.55 | −0.49 | −0.6 | |
|
| 0.033 | 0.087 | 0.82 | 0.58 | 0.62 | 0.55 |
Results of peripheral blood lymphocyte subpopulations in mild, moderate, and severe active groups of SLE (mean ± standard deviation)
| Group |
| CD3+ (%) | CD3+/CD4+ (%) | CD3+/CD8+ (%) | CD4+/CD8+ | CD3−/CD16+CD56+ (%) | CD3−/CD19+ (%) |
|---|---|---|---|---|---|---|---|
| Mild active | 28 | 70.97 ± 6.57 | 30.18 ± 4.54 | 40 ± 4.71 | 0.76 ± 0.13 | 8.75 ± 1.94 | 6.48 ± 2.01 |
| Moderate active | 31 | 70.54 ± 6.73 | 26.23 ± 4.67 | 44.16 ± 5.16 | 0.59 ± 0.17 | 8.61 ± 2.42 | 6.22 ± 1.99 |
| Severe active | 21 | 70.17 ± 6.45 | 25.33 ± 4.45 | 44.57 ± 6.54 | 0.58 ± 0.12 | 6.00 ± 2.05 | 6.10 ± 1.85 |
Correlation analysis between peripheral blood lymphocyte subpopulations of SLE and clinical testing indicators
| Name | CD3+ | CD3+/CD4+ | CD3+/CD8+ | CD4+/CD8+ | CD3−/CD16+CD56+ | CD3−/CD19+ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| SLEDAI | −0.313 | 0.005 | −0.435 | 0.001 | −0.442 | 0.003 | 0.1 | 0.934 | 0.07 | 0.856 | 0.09 | 0.812 |
| C3 | 0.394 | 0.003 | 0.45 | 0.002 | 0.406 | 0.007 | 0.163 | 0.215 | 0.149 | 0.186 | 0.177 | 0.283 |
| C4 | 0.218 | 0.091 | 0.195 | 0.227 | 0.171 | 0.353 | 0.146 | 0.281 | 0.206 | 0.115 | 0.101 | 0.420 |
| IgG | 0.089 | 0.674 | 0.234 | 0.155 | 0.056 | 0.740 | 0.188 | 0.132 | 0.092 | 0.464 | 0.083 | 0.352 |
| IgA | 0.099 | 0.522 | 0.165 | 0.213 | −0.147 | 0.257 | 0.203 | 0.071 | 0.167 | 0.322 | 0.134 | 0.264 |
| IgM | 0.141 | 0.381 | 0.066 | 0.582 | −0.101 | 0.447 | 0.135 | 0.172 | 0.071 | 0.728 | 0.138 | 0.205 |
| ESR | −0.078 | 0.634 | −0.095 | 0.825 | 0.033 | 0.542 | −0.055 | 0.796 | −0.014 | 0.561 | 0.088 | 0.432 |
| CRP | −0.056 | 0.417 | −0.087 | 0.365 | 0.052 | 0.772 | −0.044 | 0.625 | 0.095 | 0.518 | 0.069 | 0.481 |
Figure 1(a) Correlation analysis of peripheral blood CD3+ of SLE with SLEDAI; (b) Correlation analysis of peripheral blood CD3+/CD4+ of SLE with SLEDAI; (c) Correlation analysis of peripheral blood CD3+/CD8+ of SLE with SLEDAI; (d) Correlation analysis of peripheral blood CD3+ of SLE with C3; (e) Correlation analysis of peripheral blood CD3+/CD4+ of SLE with C3; (f) Correlation analysis of peripheral blood CD3+/CD8+ of SLE with C3.